Nivolumab

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Upper Gastrointestinal Cancer

Conditions

Upper Gastrointestinal Cancer

Trial Timeline

Sep 5, 2023 → Jan 25, 2024

NCT ID

NCT06361563

About Nivolumab

Nivolumab is a pre-clinical stage product being developed by Bristol Myers Squibb for Upper Gastrointestinal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT06361563. Target conditions include Upper Gastrointestinal Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03126643	Pre-clinical	Completed	—	—	Pediatric Cancer
NCT02475382	Pre-clinical	Completed	—	—	Squamous Non-Small Cell Lung Cancer
NCT06523621	Phase 2	Recruiting	Feb 28, 2025	Nov 1, 2027	Multiple Myeloma
NCT06499298	Pre-clinical	Completed	Dec 3, 2024	Apr 16, 2025	Esophageal Cancer
NCT06735781	Pre-clinical	Completed	Sep 5, 2024	Oct 1, 2024	Non-small Cell Lung Cancer (NSCLC)
NCT06421311	Pre-clinical	Terminated	Jul 30, 2024	Apr 4, 2025	Urothelial Carcinoma
NCT06452329	Pre-clinical	Completed	Feb 28, 2024	Jul 29, 2025	Gastric Cancer
NCT06003075	Phase 2	Terminated	Dec 13, 2023	Jul 5, 2024	Lung Cancer, Nonsmall Cell
NCT06361576	Pre-clinical	Completed	Sep 5, 2023	Jan 25, 2024	Upper Gastrointestinal Cancer
NCT06361563	Pre-clinical	Completed	Sep 5, 2023	Jan 25, 2024	Upper Gastrointestinal Cancer
NCT05068609	Pre-clinical	Completed	Aug 13, 2020	Oct 18, 2021	Squamous Cell Carcinoma of the Head and Neck
NCT04936399	Pre-clinical	Completed	Jun 25, 2020	Dec 3, 2021	Esophageal Squamous Cell Carcinoma
NCT04205409	Phase 2	Active	Jun 5, 2020	Aug 1, 2029	Recurrent Chronic Lymphocytic Leukemia
NCT04401774	Phase 2	Completed	May 22, 2020	Jan 22, 2026	Primary Central Nervous System Lymphoma (PCNSL)
NCT04361058	Phase 1	Withdrawn	Apr 13, 2020	Apr 20, 2021	Leukemia, Myeloid, Acute
NCT04022980	Phase 1	Completed	Mar 31, 2020	Dec 22, 2025	Brain and Nervous System
NCT04019964	Phase 2	Completed	Jan 13, 2020	Jul 3, 2025	Prostate Cancer
NCT04146324	Pre-clinical	Completed	Dec 12, 2019	May 31, 2024	Melanoma
NCT04099251	Phase 3	Active	Oct 28, 2019	Jun 29, 2027	Melanoma
NCT03981146	Phase 2	Active	Aug 28, 2019	Oct 1, 2024	Colorectal Cancer

Competing Products

20 competing products in Upper Gastrointestinal Cancer

See all competitors

Product	Company	Stage	Hype Score
Nivolumab 100 MG in 10 ML Injection	Ono Pharmaceutical	Phase 2	52
Remimazolam Tosilate	Jiangsu Hengrui Medicine	Approved	85
ABBV-950 + BOTOX + Placebo for ABBV-950	AbbVie	Phase 1	33
BOTOX + Placebo for BOTOX	AbbVie	Phase 2	52
BOTOX	AbbVie	Approved	85
MK-3475 and BCG	Merck	Phase 2	52
Montelukast + Placebo	Merck	Approved	85
Muntelukast + Placebo	Merck	Phase 3	77
IFF flavor 316 282, Paracetamol, Pseudoephedrine	Novartis	Phase 3	77
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tablets	Novartis	Phase 3	77
diclofenac potassium + nimesulide	Novartis	Approved	85
Diclofenac gel	Novartis	Approved	85
IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin	Novartis	Phase 3	77
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab	Gilead Sciences	Phase 3	76
Azithromycin SR	Pfizer	Phase 3	76
Nivolumab	Bristol Myers Squibb	Pre-clinical	22
REGN475/SAR164877 + Placebo (for REGN475/SAR164877)	Regeneron Pharmaceuticals	Phase 2	51
IPN10200 + IPN10200 Placebo + Dysport	Ipsen	Phase 1/2	38
AboBoNT-A + OnaBoNT-A	Ipsen	Approved	82
Botulinum toxin type A	Ipsen	Phase 3	74

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved